Platforms will be
BUILT & READY
before end of ICO
Already working with
Financial Market Authority Compliance
At DIGIPHARM we know people are rightly skeptical about many ICOs - but DIGIPHARM is different. We’ve chosen to become one of the first fully regulated ICOs which means we adhere to strict Swiss government regulations that protect the tokens you buy from us.
Institutions worldwide know about the potential of value-based healthcare and trust the DIGIPHARM project as well as the team behind it. We have the ingredients for a thriving business and ICO.
DIGIPHARM is pleased to announce our strategic & technical partnership with Swisscom Blockchain as our full-stack development partners, the blockchain subsidiary of the Swiss state-owned telecom provider, Swisscom.
We believe that no one should have to pay full-price for healthcare treatments that don’t work. That’s why we’re using our industry expertise to pioneer the transformation of healthcare to a value-based model. We use blockchain technology and smart contracts to provide the world's first, fully independent, value-based healthcare platforms -
helping patients worldwide to get the healthcare they deserve, at prices they can afford.
Value-based healthcare addresses the uncertainty surrounding the cost of treatment relative to patient outcomes. It rewards manufacturers & providers for improving patient outcomes, incentivises innovation, & encourages the transition to patient centric healthcare.
DIGIPHARM bypasses infrastructural limitations to:
Ready before the end of the ICO for two good reasons. The first is driven by market need, we’re already working with the world’s largest health institutions and demand for the platforms requires urgency. Secondly, because the DIGIPHARM ICO is governed by SWISS regulations, we’re obliged to protect the value of your tokens by building working platforms by the time the tokens are released. Unlike other ICO’s, DIGIPHARM is more than just an idea. You can be confident in buying DPH tokens.
World’s first blockchain & smart contract platform for performance-based flexible pricing of pharmaceuticals, medical devices, wider healthcare provision and community care.
Your fair pricing healthcare app on the blockchain.
The following projects are currently under development, they will not be ready by the ICO but remain vital to how DIGIPHARM will revitalise the healthcare industry.
The DIGIPHARM Token is a strong utility token that is key to the functionality of our platforms. As adoption of our platforms increase, the demand for the token increases. This gives token holders an incentive.
Minted & distributed to your ETH wallet after ICO
1 DPH = $ 0.45 USD
ETH , BTC
$ 5m USD
$ 15m USD
Unlike most ICOs that are unregulated, DIGIPHARM are required by FINMA to have a working model of the platform ready by the time the tokens are released following the ICO. That makes this a uniquely reliable ICO to invest in.
Concept creation & market analysis & validation
Whitepaper + Angel Investment
Core Team + advisors
Partnership Swisscom Blockchain Business Development
Incorporation in Switzerland ICO Regulatory application (FINMA)
Intellectual Property application
Proof of concept
Proof of concept validation/
Strategic partner on-boarding
ICO/Testbeds & international pilots begin
roll out production level software
Onboarding Tech Team
Technical & conceptual design
Prototype Development & release V0.1
Product development, Testing V.09 Reimburse/
Product development, Testing V.09 DIGIHEALTH
Release V1 Reimburse, Release V1 DIGIHEALTH
Pilot continuation, V2 Reimburse development
Prototype Development & release v.01 Insights
Pilot completion, V2 Reimburse development,
release V1 Insights, Reimburse Global roll out
The DIGIPHARM Team combines a passion for healthcare, industry expertise & a proven track record in all the areas needed to make this project successful.
Health economist, expert member at UN/CEFACT. Previously at Roche & health science organisations.
Health economics, market access & pricing professional with experience across the medicinal lifecycle.
Previously at Roche, LRiG, PRA health sciences, University of Swansea & International Health Care Ltd. Several publications in high impact journals. Ahmed is also a Blockchain expert in Healthcare (UN/CEFACT) at the United Nations Economic Commission for Europe.
Chief Commercial Officer
Hassan is a founding director and Chief Commercial Officer at Health iQ - a leading real world evidence agency based in the UK. His background is in health and social care, specifically in NHS informatics, public health and commissioning. He is an expert in developing solutions around real world data having spent many years consulting internationally with major pharmaceutical and medical device companies. Hassan currently holds a post as an Honorary Research Officer at Imperial College London for his work in eHealth and Big Data and is also a Committee Member of the PM Society.
Senior Manager - Value Based Healthcare
Pharmacist & Health Economist graduated from French Universities. Expert in real-world evidence generation for supporting the value of healthcare products with accurate clinical, economic and patient-based evidence. Previous HEOR & Market Access experiences within pharmaceutical & consulting companies at the national & global level. High interest in digital, entrepreneurial and disruptive projects.
Market Access and Pricing expert, previously at Pfizer, Novartis, and Takeda
Expert in global market access, pricing and reimbursements, and government affairs with 20+ years experiences in pharmaceutical and medical device industries.
Previously at Pfizer, Novartis and Takeda. Graduated from Capital Medical University in China and MBA from the US. Have led global market access projects from product launch all through the lifecycle, collaborated with multiple organizations including government agencies and academia, developed innovative solutions to optimize market and patient access.
Chief Medical Officer
Medical doctor currently practising in the UK. Graduated from King’s College London, School of Medicine. During his years training to become a general practitioner, he maintained a key interest in international healthcare by assisting hospitals in the middle east with equipment procurement, process review & staff training schemes.
Growth & internationalization Expert, International SAP/Management Consultant, tech & blockchain enthusiast with profound expertise in business development & cooperations. More than 8 years of management experience within the pharmaceutical industry with Novartis.
A strategic marketing expert with a strong background in entrepreneurship, organisational development & online community building. Johannes leverages data driven approaches to make marketing strategies effective. Before joining Swisscom Blockchain AG hehad built one of Europe's largest networks for nascent startups, cofoundme.org. Johannes has studied at the University of St. Gallen, as well as at Stellenbosch University in South Africa & the Universidad Adolfo Ibañez in Santiago de Chile.
Over 10 years of experience in web development & graphic design. I.a. front-end/ web development for EY & Swisscom Blockchain AG. Cooperation as an adviser & core team member for crypto startups.
Participation at Hack the Valley in Zug, Switzerland for Ernst & Young. One of the last projects is ICO website for Welt der Wunder.
Michael is a media designer, illustrator & product photographer with over 6 years of experience in designing & developing high quality content for clients across financial services, retail & sports. Worked for Ernst & Young, Swisscom, Welt der Wunder, he specializes in UI /UX design for web sites, vector graphic & illustrations.
Country Development & Operations
Gerard is founder of Salutem Insights, a health economic, market access and educational company. He has consulted for many major pharmaceutical companies in HTA, pricing and reimbursement strategies.
He is a qualified Health Economist, holds an MSc in Health Economics and Pharmacoeconomics and a BA in Economics and Mathematics. Gerard has vast experience in a wide variety of roles in pharmaceuticals (Helsinn Group and Clonmel Healthcare), finance (Statestreet International Bank, Deutche Bank and Bank of Luxembourg), journalism and academia.
B2B Solutions Manager
Daniel has extensive knowledge of the healthcare sector in Ireland, having worked both in hospital and primary care settings. After qualifying from UCD in Radiography, Daniel subsequently completed a Masters in Pharmacy from the University of Brighton and went on to establish a thriving community pharmacy business and osteoporosis clinic. He has a keen interest in marketing, acquired from experience garnered in the sales and marketing division of Guinness Ireland.
HEOR & Pricing Analyst
Health Economics & outcomes research professional with experience in evidence-based health service research & policy evaluation. Previously at Roche, Vista Health & the University of Lucerne. Experienced health care professional with over 12 years of providing services in the Australian, Singaporean & Swiss healthcare systems.
Anaesthetics & Critical Care Specialist. Experience in multiple medical specialties including Oncology, Cardiology, Respiratory Medicine, Emergency Medicine, General Surgery & Endocrinology. Involved in medical education & the use of technology to advance Point of Care Learning & healthcare efficiency.
Postdoctoral surgical registrar in the UK. Collaborator on regional, national & international evidence based surgery with numerous publications in high impact medical journals. Active involvement in the development of digital health technology.
Regional director MENA
Pricing, market access, & HE professional with experience in Drug Use Utilization, VBP & Health policy. Previously at Saudi Food and Drug Authority & Security Forces Hospital. Over 12 years of experience providing services in clinical and managerial sitting.
Rolf Guenter has a long lasting, proven track record as an advisory lawyer, general manager & board member of SME’s. Additionally he served as director in the insurance industry. Besides his activities in operational management, he has extensive experience from diverse, successfully managed projects.
A former manager at one of the Big 4, Sven is a recognized blockchain expert that has gained extensive experience as IT architect & project leader in numerous industries. During his career he has been involved in the development of several applications, this includes the management of technical solutions, smart contracts, marketing & overlooking general strategy.
Strategic Business Development
Lucas is an Author, TV Host, International Business Development Advisor in FinTech and Blockchain Partner @ Vesicas Fintech Consulting, Co-Founder in + 15 Companies, Author @ BlockChain in Practice / The BitCoin Paradigm / BrickCoin - A solution for today’s global financial fragility. He is Advisor, Investor and International Panelist to the Crypto World who was named as one of the 50 most influential people in Blockchain in 2016.
Health Technology Advisor
A dynamic global business leader & technology executive. Sam is currently the Managing Director of Healthcare & Life Sciences at Luxoft, he was formerly the Global Head of R&D IT at Novartis. He has a strong track record of business partnership, digital transformation, successful IT delivery & talent development across diverse geographies & functional areas.
Sam is passionate about leveraging technology to realise business value & high performance in Healthcare, Life Sciences & data driven companies. He is equipped with an agile, collaborative & entrepreneurial mind-set combined with a willingness to challenge his team, peers & business executives to achieve ambitious goals.
Quality & Testing
Experienced Test Manager focused on improving quality delivery & improving processes. Has a strong QA delivery track record in the Health Care, Financial, Transportation, & Public Sector industries. Currently leading the Mobile & SAP QA teams at IBMs NS CIC.
Life Sciences Blockchain Advisor
Waldemar Scherer is Head of Enterprise Blockchain at Swisscom Blockchain. With his team he advises private, institutional & governmental clients in adopting blockchain technology to their business operations. As a former manager at EY & consultant at HP, Waldemar is an experienced IT advisory professional. In his free time, he is an avid sportsman, participating in obstacle runs, scuba dives & climbing tours.
Global health economics manager at Roche, the worlds largest biotech company, with a keen interest in the influence of technology on the pharmaceutical reimbursement process. Developed intra-organisational health economic modelling apps & authored numerous publications in high impact journals.
Health economist at NICE UK, with previous experience in HTA & MTA appraisals at leading academic institutions such as the Centre for Health Economics at the University of York & the Academic Unit of Health Economics at the University of Leeds.
Enterprise Blockchain Advisor
Kamal has extensive experience in managing & delivering industrial level solutions using SAP & blockchain technology. Formerly a senior SAP advisor & blockchain engineer at one of the Big 4. He is an expert in systems integration with a thorough understanding of regulatory compliance, financial cryptography & data security.
James Gannon is the Global Head of Technical Compliance for Emerging Technologies at Novartis AG. Based in Basel Switzerland, James has over 10 years of experience in advising large corporations & high technology startups on cyber security policy & quality regulatory affairs as they relate to adoption of new & emerging technologies in the healthcare market.
Visionary, Futurist, and a blockchain consultant
Alice Hlidkova is a visionary, futurist, and a blockchain consultant and writer, based in Chicago, USA. She has vast experience in helping startups scale international markets successfully. Alice founded her creative consulting agency, Through the Changing Glass LLC to advise tech startups on positioning and capital raise in Silicon Valley. She is also the co founder of New Economies LTD the media company and the parent of neweconomies.com, a leading blockchain news portal.
DIGIPHARM combines industry expertise & revolutionary blockchain technology to pioneer the transformation of healthcare to a value-based approach.
Businesses built using the blockchain are the future. And value-based healthcare is the future of the healthcare industry. DIGIPHARM combines both to solve the problems of a multi-trillion dollar industry. This is your chance to be among the first in the world to support the idea & benefit from the platform - as well as the potential increase in token demand as more people buy tokens & use the platform globally.
DPH will be available on exchange once ICO concludes. We can’t give an exact date at this time, but we are actively seeking exchange partnerships.
Just click any ‘Buy Tokens Now’ button & follow the instructions.
There are 50,000,000 (fifty million) DPH tokens available in total for public sale. 15,000,000 available in the presale. 35,000,000 in the main sale. The total supply of DPH is 100,000,000.
In the event the softcap isn’t met, all funds will be returned to investors.
There are no minimum or maximum investment amounts
There is a 30% presale bonus. During the main sale, the cost per token depends at which stage you buy. There are stage 1 & 2 Bonus of 20% & 10% respectively. Towards the end of the sale the token will only be available at the full price of $0.45 per token.
Yes. DPH is an ERC20 token, & will be available on exchange once ICO concludes. We can’t give an exact date at this time, but we are actively seeking exchange partnerships.
To be announced
DPH tokens will be used for access rights to the Digihealth platform. Research organisations will require DPH tokens when constructing and generating patient-relevant studies on the platform.
Payers/manufacturers will be required to use DPH tokens to initiate or execute smart contracts within the Reimburse module and to enroll individual patients on these smart contracts, i.e. DPH tokens will be used to facilitate the process of annexing patients to innovative pricing and reimbursement agreements.
DPH will be used as the utility token to power each interaction with the Insights database by healthcare stakeholders i.e. DPH tokens will be used for access rights or specific data requests from the Insights platform.
DPH tokens will be used for access rights to the Evolve platform. DPH tokens will also be required to access comprehensive data and reviews related to advertised health technologies and projects.
DPH tokens will be used for specific data requests by research organisations on the MYHEALTH platform.
Tokens will be distributed within 4 weeks after the end of the ICO, & transferrable immediately once distributed.
Any questions? Reach out to us and we’ll get back to you shortly.